Sumatriptan succinate
SIGMA/S1198 - ≥98% (HPLC), solid
Synonym: 3-
CAS Number: 103628-48-4
Empirical Formula (Hill Notation): C14H21N3O2S · C4H6O4
Molecular Weight: 413.49
MDL Number: MFCD00902856
Linear Formula: C14H21N3O2S · C4H6O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | solid |
| InChI | 1S/C14H21N3O2S.C4H6O4/c1- |
| InChI key | PORMUFZNYQJOEI-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | OC(=O)CCC(O)=O.CNS(=O)(=O |
| solubility | H2O: >20 mg/mL |
| Biochem/physiol Actions: | Sumatriptan succinate has the ability to constrict human cranial arteries. This 5-HT1 receptor agonist can be used to treat migraine. |
| Biochem/physiol Actions: | Sumatriptan succinate is a 5-HT1 serotonin receptor agonist. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | GHS08 |
| Signal word | Warning |
| Hazard statements | H361d - H412 |
| Precautionary statements | P202 - P273 - P280 - P308 + P313 - P405 - P501 |
| Hazard Codes | Xi |
| Risk Statements | 41 |
| Safety Statements | 26-39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


